Skip to main content
main-content

06-06-2021 | ASCO 2021 | Conference coverage | Video

OlympiA: Adjuvant olaparib delays recurrence of BRCA-mutant breast cancer

Judy Garber reports on the phase 3 OlympiA study suggesting that adjuvant olaparib could be an option for the treatment of patients with early-stage breast cancer and germline BRCA variants (5:00).

Read transcript

2021 ASCO Annual Meeting coverage

Access news and expert commentary from the 2021 ASCO Annual Meeting

Image Credits